Research programme: Hematopoietic progenitor kinase 1 modulators - Shenzhen Forward Pharmaceutical
Alternative Names: HPK1 modulators - Shenzhen Forward PharmaceuticalLatest Information Update: 14 Jan 2026
At a glance
- Originator Shenzhen Forward Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Hematopoietic progenitor kinase 1 modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 08 Jan 2026 Preclinical trials in Cancer in China (Parenteral) prior to January 2026 (Shenzhen Forward Pharmaceutical pipeline, January 2026)